Physicochemical and toxicological characterization of a new generic iron sucrose preparation

Arzneimittel-Forschung/Drug Research

Volumn 61, Issue 2, 2011, Pages 112-119

  Meier, Thomas ^a   Schropp, Patricia ^b   Pater, Christian ^a   Leoni, Anne Laure ^b   Khov Tran, Van Van ^c   Elford, Peter ^c  

^a Cilag AG   (Switzerland)

^b BSL BIOSERVICE Scientific Laboratories GmbH   (Germany)

^c Azad Pharma AG   (Switzerland)

Author keywords

Iron sucrose azad; Iron sucrose, generic; Pysicochemical characterization; Toxicity

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; FERRIC HYDROXIDE SUCROSE; GLUTATHIONE PEROXIDASE; RECOMBINANT ERYTHROPOIETIN; SUPEROXIDE DISMUTASE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; ATOMIC FORCE MICROSCOPY; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG DEGRADATION; DRUG FORMULATION; DRUG TOLERABILITY; ENZYME ACTIVITY; FEMALE; HEMATOPOIESIS; HISTOLOGY; IRON BLOOD LEVEL; IRON KINETICS; MALE; NONHUMAN; PHYSICAL CHEMISTRY; POLAROGRAPHY; RAT;

EID: 79952341732     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296176     Document Type: Article

References (27)

1. Hsu C, McCulloch CE, Curhan GC. Iron status and haemoglobin level in chronic renal insufficiency. J Am Soc Nephrol. 2002;13:2783-6. (Pubitemid 35216049)
2. Panesar A and Agarwal R. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease. Am J Kidney Dis. 2002;40:924-31. (Pubitemid 35265471)
3. Fishbane S. Safety in iron management. Am J Kidney Dis. 2003;41:S18-26.
4. Danielson BG. Structure, chemistry and pharmacokinetics of intravenous iron agents. J Am Soc Nephrol. 2004;15:S93-8.
5. Agarwal R. Transferrin saturation with intravenous irons: An in vitro study. Kidney Int. 2004;66:1139-44. (Pubitemid 39121020)
6. Drüeke T, Witko-Sarsat V, Massy Z, Descamps-Latscha B, Guerin AP, Marchais SJ, et al. Iron therapy, advanced oxidation protein products, and carotid artery intima-media thickness in end-stage renal disease. Circulation. 2002;106:2212-7. (Pubitemid 35222215)
7. Zager RA. Parenteral iron compounds: potent oxidants but mainstays of anemia management in chronic renal disease. Clin J Am Soc Nephrol. 2006;1:S24-31.
8. Geisser P, Baer M, Schaub E. Structure/histotoxicity relationship of parenteral iron preparations. Drug Res. 1992;42:1439-52. (Pubitemid 23007362)
9. Van Wyck DB, Danielson BG, Arnoff GR. Making sense: A scientific approach to intravenous iron therapy. J Am Soc Nephrol. 2004;15:S91-2.
10. Besarab A, Amin N, Ahsan M, Vogel SE, Zazuwa G, Frinak S, et al. Optimization of epoetin therapy with intravenous iron therapy in hemodialysis patients. J Am Soc Nephrol. 2000;11:530-8. (Pubitemid 30115083)
11. Schiesser D, Binet I, Tsinalis D, Dickenmann M, Keusch G, Schmidli M, et al. Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients. Neprol Dial Transplant. 2006;21:2841-5. (Pubitemid 44542240)
12. Toblli J, Cao G, Oliveri L, Angerosa M. Differences between original intravenous iron sucrose and iron sucrose similar preparations. Arzneimittelforschung. 2009;59:176-90.
13. Toblli J, Cao G, Oliveri L, Angerosa M. Differences between the original intravenous iron sucrose complex Venofer. and the iron sucrose similar Generis. and potential implications. Port J Nephrol Hypert. 2009;23:53-63.
14. Kudasheva D, Lai J, Ulman A, Cowman MK. Structure of nanoparticles in parenteral formulations. J Inorg Biochem. 2004;98:1757-69.
15. Erni I, Oswald N, Rich HW, Schneider W. Chemical characterization of iron (III)-hydroxide-dextrin complexes. Arzneimittelforschung 1984;34:1555-9.
16. OECD Environmental Health and Safety Publications: Principles of Good Laboratory Practice and Compliance Monitoring, No.1. Environment Directorate, Organisation for Economic Co-operation and Development. OECD: Paris; 1998.
17. Kudasheva DS, lai J, Ulman A, Cowman MK. Structure of carbohydrate-bound polynuclear iron oxyhydroxide nanoparticles in parenteral formulations. J Inorg Biochem. 2004;98:1757-69. (Pubitemid 39456424)
18. Zanen AL, Adriaansen HJ, van Bommel EF, Posthuma R, Th de Jong GM. "Oversaturation" of transferrin after intravenous ferric gluconate (Ferrlecit®) in haemodialysis patients. Nephrol Dial Transplant. 1996;11:820-42.
19. th 2000.
20. Legssyer R, Geisser P, McArdle H, Crichton RR, Ward RJ. Comparison of injectable iron complexes in their ability to iron load tissues and induce oxidative stress. Biometals. 2003;16:425-33. (Pubitemid 36356773)
21. Summary of Product Characteristics (SPC) for Venofer 20 mg/ml Solution for Injection [Internet]. Electronic Medicines Compedium. Datapharma, London; 2006. [Cited: 2010 Dec 8] Available from: http://www.medicines.org.uk/EMC/ medicine/14438/SPC/Venofer+20+mg+ml+Solution+for+Injection.
22. Chandler G, Harchowal J, Macdougall I.C. Intravenous iron sucrose: establishing a safe dose. Am Kidney Dis. 2001;38:988-91.
23. Kooistra MP, Kersting S, Gosriwatana I, Lu S, Nijhoff-Schutte J, Hider RC, et al. Nontransferrin-bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion. Eur J Clin Invest. 2002;32:36-41. (Pubitemid 41704986)
24. Parkkinen J, von Bonsdorff L, Peltonen S, Grönhagen-Riska C, Rosenlöf K. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i. v. iron-saccharate administration. Nephrol Dial Transplant. 2000;15:1827-34.
25. Espósito BP, Breuer A, Stotkli I, Cabantchik ZI. Labile iron in parenteral iron formulations and its potential for generating plasma nontransferrin-bound iron in dialysis patients. Eur J Clin Invest. 2000;32:42-9. (Pubitemid 41704987)
26. Nyovad O, Danielsen H, Madsen S. Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients. Lancet. 1994;344:1305-6. (Pubitemid 24334711)
27. Macdougall IC, Chandler G, Elston O, Harchowal J. Beneficial effects of adopting an aggressive intravenous iron policy in a hemodialysis unit. Am J Kidney Dis. 1999;34:S40-6.